BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND BTG1, P62324, 694, ENSG00000133639 AND Treatment
33 results:

  • 1. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
    Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
    Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial.
    Qiu KY; Wang JY; Huang LB; Li CG; Xu LH; Liu RY; Chen HQ; Ruan YS; Zhen ZJ; Li CK; Fang JP
    Am J Hematol; 2023 Jun; 98(6):869-880. PubMed ID: 36877527
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Emerging role of anti-proliferative protein btg1 and BTG2.
    Kim SH; Jung IR; Hwang SS
    BMB Rep; 2022 Aug; 55(8):380-388. PubMed ID: 35880434
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
    Huang J; Chan SC; Lok V; Zhang L; Lucero-Prisno DE; Xu W; Zheng ZJ; Elcarte E; Withers M; Wong MCS;
    Lancet Haematol; 2022 Sep; 9(9):e670-e677. PubMed ID: 35843248
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid leukemia by Multiparameter Flow Cytometry].
    Jin Y; Wang AY; Wang XB; Yang HZ; Liu X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):737-743. PubMed ID: 35680798
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Indications for cryopreservation and autotransplantation of ovarian tissue.
    Gjeterud J; Kristensen SG; Fedder J
    Tidsskr Nor Laegeforen; 2021 Oct; 141(2021-15):. PubMed ID: 34726041
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
    Gupta SK; Bakhshi S; Kamal VK; Gupta R; Sharma P; Pushpam D; Sahoo RK; Sharma A
    Leuk Res; 2021 Dec; 111():106683. PubMed ID: 34371436
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic leukemia with Prognosis.
    Hosein Pour Feizi A; Zeinali S; Toporski J; Sheervalilou R; Mehranfar S
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3493-3500. PubMed ID: 33369444
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Modulation of FLT3 signal transduction through cytoplasmic cysteine residues indicates the potential for redox regulation.
    Böhmer A; Barz S; Schwab K; Kolbe U; Gabel A; Kirkpatrick J; Ohlenschläger O; Görlach M; Böhmer FD
    Redox Biol; 2020 Jan; 28():101325. PubMed ID: 31606550
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Production of a novel N-terminal PEGylated crisantaspase.
    Torres-Obreque K; Meneguetti GP; Custódio D; Monteiro G; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    Biotechnol Appl Biochem; 2019 May; 66(3):281-289. PubMed ID: 30597637
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumor suppressors btg1 and BTG2: Beyond growth control.
    Yuniati L; Scheijen B; van der Meer LT; van Leeuwen FN
    J Cell Physiol; 2019 May; 234(5):5379-5389. PubMed ID: 30350856
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
    Herling CD; Abedpour N; Weiss J; Schmitt A; Jachimowicz RD; Merkel O; Cartolano M; Oberbeck S; Mayer P; Berg V; Thomalla D; Kutsch N; Stiefelhagen M; Cramer P; Wendtner CM; Persigehl T; Saleh A; Altmüller J; Nürnberg P; Pallasch C; Achter V; Lang U; Eichhorst B; Castiglione R; Schäfer SC; Büttner R; Kreuzer KA; Reinhardt HC; Hallek M; Frenzel LP; Peifer M
    Nat Commun; 2018 Feb; 9(1):727. PubMed ID: 29463802
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.
    Singh M; Bhatia P; Trehan A; Varma N; Sachdeva MS; Bansal D; Jain R; Naseem S
    Leuk Res; 2018 Mar; 66():79-84. PubMed ID: 29407587
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
    Schetelig J; de Wreede LC; van Gelder M; Andersen NS; Moreno C; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Henseler A; van Biezen A; Bornhäuser M; Schönland SO; Kröger N
    Bone Marrow Transplant; 2017 Apr; 52(4):552-560. PubMed ID: 28112746
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia.
    Okamoto Y; Koga Y; Inagaki J; Ozono S; Ueda K; Shimoura M; Itonaga N; Shinkoda Y; Moritake H; Nomura Y; Nakayama H; Hotta N; Hidaka Y; Shimonodan H; Suga N; Tanabe T; Nakashima K; Fukano R; Kawano Y
    Int J Hematol; 2016 Feb; 103(2):202-9. PubMed ID: 26586463
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
    Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
    Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
    Moorman AV; Enshaei A; Schwab C; Wade R; Chilton L; Elliott A; Richardson S; Hancock J; Kinsey SE; Mitchell CD; Goulden N; Vora A; Harrison CJ
    Blood; 2014 Aug; 124(9):1434-44. PubMed ID: 24957142
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
    Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.